| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3-Bromo-5-chloropyridine interacts with various molecular targets within cells. The presence of bromine and chlorine substituents enhances its binding affinity to specific proteins and enzymes. The compound's halogenated pyridine structure allows it to participate in various chemical reactions relevant to drug discovery. Its ability to interact with proteins and enzymes makes it valuable for studying biochemical pathways. The compound's biological activity is primarily attributed to its chemical reactivity.
|
|---|---|
| ln Vitro |
In vitro, 3-bromo-5-chloropyridine is used as a biochemical reagent in life science research. It plays a significant role in biochemical reactions. The compound's halogenated structure allows it to interact with various proteins and enzymes. It serves as a sulfonylation reagent for organic synthesis and drug discovery. Cellular assays typically evaluate its interactions with molecular targets or its effects on cell function. The compound's binding affinity to specific proteins can be evaluated in vitro.
|
| ln Vivo |
In vivo data for 3-bromo-5-chloropyridine is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Its primary value lies in its use as a synthetic intermediate and biochemical reagent. Specific in vivo data for the parent compound is not available in the public literature. The compound's halogenated structure may influence its metabolic stability and pharmacokinetics.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3-bromo-5-chloropyridine typically evaluate its interactions with proteins and enzymes. A standard assay protocol involves incubating the compound with purified proteins or enzymes in appropriate buffer systems. The compound is dissolved in DMSO and diluted to working concentrations. Binding affinity is assessed using techniques such as surface plasmon resonance, isothermal titration calorimetry, or fluorescence polarization. IC₅₀ or Kd values are calculated from dose-response curves. The compound's halogenated structure enhances binding affinity.
|
| Cell Assay |
Cellular assays for 3-bromo-5-chloropyridine typically evaluate its effects on cell function or its interactions with cellular targets. A standard protocol involves culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound (typically 0.1-100 μM). Cell viability is assessed using MTT or similar assays. The compound's effects on specific cellular pathways or protein targets can be evaluated by Western blot or other biochemical assays. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 3-bromo-5-chloropyridine are not standard, as it is a research reagent rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would typically be conducted on the final pharmaceutical products synthesized using this building block. The compound's primary value lies in its use as a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3-bromo-5-chloropyridine is limited, as it is primarily a research reagent. The compound has a molecular weight of 192.44 g/mol. It is stored as a solid at room temperature. As a halogenated pyridine, the compound may undergo metabolic dehalogenation and oxidation. The bromine and chlorine substituents may influence the compound's lipophilicity and metabolic stability. Specific ADME data is not available in the public literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-bromo-5-chloropyridine is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
3-Bromo-5-chloropyridine (CAS 73583-39-8) is a biochemical reagent with the molecular formula C₅H₃BrClN. It interacts with various molecular targets within cells and serves as a sulfonylation reagent for organic synthesis and drug discovery. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis.
|
| Molecular Formula |
C5H3BRCLN
|
|---|---|
| Molecular Weight |
192.44
|
| Exact Mass |
190.913
|
| CAS # |
73583-39-8
|
| PubChem CID |
606256
|
| Appearance |
Gray to brown solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
194.7±20.0 °C at 760 mmHg
|
| Melting Point |
80-82°C
|
| Flash Point |
71.5±21.8 °C
|
| Vapour Pressure |
0.6±0.4 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
78.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=NC=C1Br)Cl
|
| InChi Key |
BELDOPUBSLPBCQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3BrClN/c6-4-1-5(7)3-8-2-4/h1-3H
|
| Chemical Name |
3-bromo-5-chloropyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1964 mL | 25.9821 mL | 51.9642 mL | |
| 5 mM | 1.0393 mL | 5.1964 mL | 10.3928 mL | |
| 10 mM | 0.5196 mL | 2.5982 mL | 5.1964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
